Immunome Inc.
About Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.9M
- Net income
- -$212.4M
- Total assets
- $683.2M
- Market cap
- $2.1B
- Operating margin
- -3228.8%
- Net margin
- -3060.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.9M
- Operating expenses
- $231.1M
- Operating income
- -$224.1M
- Income tax
- $0
- Net income
- -$212.4M
- EPS (basic)
- $-2.43
- EPS (diluted)
- $-2.43
Balance sheet
- Total assets
- $683.2M
- Current assets
- $660.8M
- Total liabilities
- $48.8M
- Current liabilities
- $45.0M
- Shareholders’ equity
- $634.3M
Cash flow
- Operating cash flow
- -$190.9M
- Investing cash flow
- $60.8M
- Financing cash flow
- $640.4M
- Net cash flow
- $510.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.1B
- EPS (diluted)
- $-2.43
- Shares outstanding
- 113.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 2, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $212.4M in FY2025.
- Revenue grew 69510% from FY2021 to FY2025.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immunome Inc..
Write a review
News about Immunome Inc.
News & sentiment via Polygon.io
